文献速递免疫规划传染病防控与疫情报告

高效价多价口蹄疫病毒疫苗对牛抵抗新兴A/ASIA/G-VII谱系田间病毒异源攻毒的效力

Efficacy of a high-potency multivalent foot-and-mouth disease virus vaccine in cattle against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage.
PubMed 文献 · Vaccine · 2018-03-02

2015年中东口蹄疫疫情由A/ASIA/G-VII谱系引起,世界参考实验室体外匹配显示该谱系田间病毒与地区现用疫苗匹配不佳。研究将16头牛接种含A-SAU-95和A-IRN-05的同源效价至少6PD50多价疫苗、2头不接种对照,21天后用A/IRN/22/2015田间分离株舌部攻毒,结果仅56.3%接种牛受保护,对照均发生全身性口蹄疫。

要点

  • 16头牛接种含A-SAU-95和A-IRN-05、同源效价至少6PD50的多价疫苗,2头为未接种对照。
  • 攻毒后7/16接种牛出现至少一个足部病变,仅56.3%被定义为保护,2头对照均发生全身性口蹄疫。
  • A-SAU-95血清滴度升高与保护概率显著增加相关(p=0.03),A-IRN-05不显著(p=0.42)。

核心结论

  • 该疫苗不适用于无口蹄疫国家的紧急使用,但在反复预防接种的地方性流行国家可能部分有效。
  • 对于紧急反应性接种,研究结果支持应开发针对A/ASIA/G-VII谱系量身定制的新疫苗株。

研究设计与样本

  • 研究将16头牛接种含两个A血清型成分(A-SAU-95和A-IRN-05)、同源效价至少6PD50的多价口蹄疫疫苗,另2头牛不接种作为对照。
  • 接种21天后,全部18头牛按欧洲药典PPG试验条件,用A/ASIA/G-VII谱系的田间分离株A/IRN/22/2015经舌部接种攻毒。

主要发现

  • 2头对照牛均发生全身性口蹄疫,7/16接种牛出现至少一个足部病变,仅56.3%被定义为保护。
  • A-SAU-95血清滴度升高与保护概率显著增加相关(p=0.03),A-IRN-05血清滴度与保护概率增加不显著(p=0.42)。
  • 血液和鼻拭子口蹄疫病毒分析提示,即使动物出现足部病变,接种也减少病毒排出和潜在传播。

临床怎么用

  • 作者认为该疫苗不适用于无口蹄疫国家的紧急情况,但在反复预防接种的地方性流行国家可能部分有效。
  • 作者认为紧急反应性接种应开发针对A/ASIA/G-VII谱系量身定制的新疫苗株。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2015, outbreaks of foot-and-mouth disease (FMD) in the Middle East were discovered to be caused by a viral lineage (A/ASIA/G-VII), which has recently emerged from the Indian sub-continent. In vitro vaccine matching data generated by the World Reference Laboratory (WRLFMD) indicated that A/ASIA/G-VII field viruses were poorly matched with vaccines (A-SAU-95, A22 IRQ and A-IRN-05) that are already used in the region. In order to assess the likely performance of one of these commercially available FMD vaccines, sixteen cattle were vaccinated with a polyvalent vaccine which contained two serotype A components (A-SAU-95 and A-IRN-05) with a homologous potency of at least 6PD50, and two cattle were left unvaccinated as controls. Twenty-one days later, all 18 cattle were challenged by tongue inoculation with an FMDV field isolate A/IRN/22/2015 from the A/ASIA/G-VII lineage, in line with the European Pharmacopeia PPG test conditions. The two control animals developed generalised FMD, and 7/16 vaccinated animals developed at least one foot lesion, thus only 56.3% were defined as protected. For the vaccine components, there was a significant increase in the probability of protection with increasing serological titres for A-SAU-95 (p = 0.03), but not for A-IRN-05 (p = 0.42). Analysis of FMDV in blood and nasal swabs suggested that vaccination reduced shedding and potential onward spread of FMD virus even if the animal developed foot lesions. In summary, the results from this study suggest that whilst this vaccine would not be appropriate for use in an emergency situation (in previously FMD-free countries), it may be partially effective in the field in endemic countries where repeat prophylactic vaccination is practiced. For emergency reactive vaccination, the findings from this study support the idea that a new vaccine strain should be developed that is tailored to the A/ASIA/G-VII lineage.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Waters R, Ludi AB, Fowler VL, et al. Efficacy of a high-potency multivalent foot-and-mouth disease virus vaccine in cattle against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage. Vaccine. 2018. PMID: 29506922. doi:10.1016/j.vaccine.2018.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。